CGTX ▲ +6.7% - Cognition Therapeutics, Inc.
$CGTX - Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
22-OCT-2026 06:00 AM ET
Share this post
More filings for $CGTX
CGTX ▲ +2.4% - Cognition Therapeutics, Inc.Oct 13, 2026CGTX ▲ +2.1% - Cognition Therapeutics, Inc.Sep 29, 2026CGTX ▲ +1.0% - Cognition Therapeutics, Inc.Sep 8, 2026
View full $CGTX filing history →💬 Comments
Loading comments…
Leave a comment